Quetiapine Use in Patients with Pacemakers: Cardiac Safety Considerations
Primary Cardiac Safety Concerns
- Quetiapine is classified as a second-generation antipsychotic with documented potassium channel blockade that increases the risk of ventricular arrhythmias and sudden cardiac death, with an adjusted odds ratio of 1.29 (95% CI: 1.07-1.56) for ventricular arrhythmia and/or sudden cardiac death, according to the European Heart Journal 1
- The mechanism involves human ether-a-go-go-related gene (hERG) potassium channel blockade, which can precipitate torsades de pointes, as reported in the European Heart Journal 1
Pre-Treatment Cardiac Assessment
- Obtain baseline ECG to measure corrected QT interval (QTc); treatment should be reconsidered if QTc >500 ms, as recommended by the European Heart Journal 1
- Assess cardiac risk profile including history of arrhythmias, impaired left ventricular function, and concurrent medications, according to the European Heart Journal 1
- Check serum electrolytes, particularly potassium and magnesium, as hypokalaemia significantly increases arrhythmia risk, as stated in the European Heart Journal 1
Pacemaker-Specific Considerations
- The presence of a pacemaker indicates underlying conduction system disease, placing patients at inherently higher risk for drug-induced arrhythmias, as reported in the Journal of the American College of Cardiology 2, 3, 4
- Patients with pacemakers for bradycardia-tachycardia syndrome are particularly vulnerable, as antipsychotics can worsen both components, according to Circulation 5, 6
Monitoring Protocol During Treatment
- Perform follow-up ECG after initiating quetiapine and with each dose adjustment, as recommended by the European Heart Journal 1
- Monitor for QTc prolongation; if QTc exceeds 500 ms or increases >60 ms from baseline, treatment should be re-evaluated, according to the European Heart Journal 1
Drug Interaction Management
- Concomitant use of other QT-prolonging drugs (Class IA or Class III antiarrhythmics) should be avoided, as stated in Praxis Medical Insights: Practical Summaries of Clinical Guidelines 10
- Medications that inhibit CYP3A4 metabolism can increase quetiapine levels and cardiac risk, as reported in Praxis Medical Insights: Practical Summaries of Clinical Guidelines 10